Niagen Bioscience Financials - Benzinga

Niagen Bioscience Inc

NAGENASDAQ

Trade with Public

Trade with Public

$3.29

0.082.49%

At close: Aug 28, 5:00 PM EST

$3.29

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Niagen Bioscience Financials

Niagen Bioscience (NAGE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est

Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.

Benzinga Newsdesk

PRO
Niagen Bioscience Q2 EPS $0.01 Misses $0.02 Estimate, Sales $29.785M Miss $30.690M Estimate

Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.02 by 50 percent. This is a 75 percent decrease over earnings of $0.04 per share from the

Benzinga Newsdesk

Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED)

Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside investments in injections and skincare.

Eva Mathew

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Niagen Expects 2026 Net Sales To Increase Between 10-15% YoY, Excluding 2025 Net Sales Attributable To The Analytical Reference Standards And Services Segment

2026 Full Year OutlookNet sales: Increasing between 10-15% year-over-year excluding 2025 net sales attributable to the Analytical Reference Standards and Services segment, driven primarily by e-commerce business and new

Benzinga Newsdesk

PRO
Niagen Bioscience Q1 EPS $0.07 Beats $0.06 Estimate, Sales $31.474M Beat $30.950M Estimate

Benzinga Newsdesk